| abstract |
The present invention relates to a ligand having a binding site having binding specificity for an endogenous target compound, but comprising a moiety (eg, dAb) that does not substantially inhibit the activity of said endogenous target compound. Preferably, the ligand does not bind to the active site of the endogenous target compound. The present invention relates to the use of said ligands in the manufacture of a medicament for increasing the half-life, bioavailability, activity or amount of an endogenous target compound that binds said land. |